Understanding SARS-CoV-2-Mediated Inflammatory Responses: From

Currently there is no effective antiviral therapy for SARS-CoV-2 infection, which frequently leads to fatal inflammatory responses and acute lung injury. Here, we discuss the various mechanisms of SARS-CoV-mediated inflammation. We also assume that SARS-CoV-2 likely shares similar inflammatory responses. Potential therapeutic tools to reduce SARS-CoV-2-induced inflammatory responses include various methods to block FcR activation. In the absence of a proven clinical FcR blocker, the use of intravenous immunoglobulin to block FcR activation may be a viable option for the urgent treatment of pulmonary inflammation to prevent severe lung injury. Such treatment may also be combined with systemic anti-inflammatory drugs or corticosteroids. However, these strategies, as proposed here, remain to be clinically tested for effectiveness.

Innate immunological pathways in COVID-19 pathogenesis

Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome

Pathogenesis of COVID-19-induced ARDS: implications for an ageing population

Immune mechanisms underlying COVID-19 pathology and post-acute sequelae of SARS-CoV-2 infection (PASC)

SARS-CoV-2 and innate immunity: the good, the bad, and the “goldilocks”

What is the role of T cells in COVID-19 infection? Why immunity is about more than antibodies - The Centre for Evidence-Based Medicine

Understanding the pivotal roles of ACE2 in SARS-CoV-2 infection: from structure/function to therapeutic implication, Egyptian Journal of Medical Human Genetics

COVID-19 - Wikipedia

JCI Insight - Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases

PDF] The Intersection of COVID-19 and Autoimmunity: What is Our Current Understanding?

COVID-19 infection: an overview on cytokine storm and related interventions, Virology Journal

Two Years into the COVID-19 Pandemic: Lessons Learned

Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools